- Home
- TAK vs IQV Comparison
TAK vs IQV Comparison
Compare TAK & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- IQV
- Stock Information
- Founded
- TAK 1781
- IQV 1982
- Country
- TAK Japan
- IQV United States
- Employees
- TAK N/A
- IQV N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- TAK Health Care
- IQV Health Care
- Exchange
- TAK Nasdaq
- IQV Nasdaq
- Market Cap
- TAK 42.2B
- IQV 35.7B
- IPO Year
- TAK N/A
- IQV 2013
- Fundamental
- Price
- TAK $15.04
- IQV $181.34
- Analyst Decision
- TAK
- IQV Strong Buy
- Analyst Count
- TAK 0
- IQV 18
- Target Price
- TAK N/A
- IQV $248.72
- AVG Volume (30 Days)
- TAK 1.5M
- IQV 1.5M
- Earning Date
- TAK 05-08-2025
- IQV 05-01-2025
- Dividend Yield
- TAK 3.39%
- IQV N/A
- EPS Growth
- TAK 15.39
- IQV 2.74
- EPS
- TAK 0.83
- IQV 7.49
- Revenue
- TAK $29,124,927,177.00
- IQV $15,405,000,000.00
- Revenue This Year
- TAK $8.53
- IQV $4.30
- Revenue Next Year
- TAK N/A
- IQV $6.17
- P/E Ratio
- TAK $36.00
- IQV $24.21
- Revenue Growth
- TAK 9.83
- IQV 2.81
- 52 Week Low
- TAK $12.58
- IQV $179.28
- 52 Week High
- TAK $15.22
- IQV $256.76
- Technical
- Relative Strength Index (RSI)
- TAK 70.24
- IQV 37.22
- Support Level
- TAK $14.83
- IQV $180.67
- Resistance Level
- TAK $15.22
- IQV $193.01
- Average True Range (ATR)
- TAK 0.17
- IQV 5.26
- MACD
- TAK 0.03
- IQV -0.33
- Stochastic Oscillator
- TAK 84.84
- IQV 12.55
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.